Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Benchmark Research

Neither a doctor nor a teaching hospital

Research payments

$23,863,257

4,468 payments

Through program year 2025, Benchmark Research is reported as receiving $23,863,257 in research payments, across 4,468 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $609,536 90
2024 Research $319,966 159
2023 Research $7,097,736 2,993
2022 Research $9,508,860 742
2021 Research $5,161,224 195
2020 Research $661,440 116
2019 Research $504,495 173

Breakdown

Who paid Research payments · program years 2019–2025
  1. Moderna TX, Inc. $13,641,209 3,763 payments
  2. Regeneron Pharmaceuticals, Inc. $6,523,966 51 payments
  3. Merck Sharp & Dohme Corporation $1,481,397 94 payments
  4. AstraZeneca UK Limited $1,118,692 12 payments
  5. GlaxoSmithKline, LLC. $468,834 194 payments
  6. Pfizer Inc. $294,525 136 payments
  7. Seqirus USA Inc $130,486 131 payments
  8. AstraZeneca Pharmaceuticals LP $88,800 7 payments
  9. ITI, Inc. $32,996 16 payments
  10. OraSure Technologies Inc. $31,443 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers $6,481,937 34 payments
  2. A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older $5,676,677 322 payments
  3. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $1,411,796 37 payments
  4. A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 $1,316,794 1,398 payments
  5. A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants $1,068,765 133 payments
  6. A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment $1,060,042 10 payments
  7. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $556,882 892 payments
  8. A PHASE 2a, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, DOSE-CONFIRMATION STUDY TO EVALUATE THE SAFETY, REACTOGENICITY, AND IMMUNOGENICITY OF MRNA-1273 SARS-COV-2 VACCINE IN ADULTS AGED 18 YEARS AND OLDER $529,124 8 payments
  9. A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Concomitant Administration of Either 23-Valent Pneumococcal Polysaccharide Vaccine or 15-Valent Pneumococcal Conjugate Vaccine with a Booster Dose of SARS-CoV-2 mRNA Vaccine in Healthy Adults 50 Years of Age or Older. $502,311 12 payments
  10. Phase 1/2, randomized, observer-blind to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1073 and co-administered mRNA-1273 and mRNA-1010 vaccines compared to mRNA-1273 and mRNA-1010 vaccines along in healthy adults 18 to 75 years $484,329 41 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record